Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32689999 | 0.89 | TSHR (0.35) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4246548 | 0.80 | ALDH1A1 (0.37) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL24864597 | 0.80 | DAO (0.32) | — | |
| SCHEMBL12534277 | 0.79 | — | — | |
| SCHEMBL11703082 | 0.77 | ALDH1A1 (0.40) | ALDH1A1LMNAHPGD | |
| SCHEMBL16271560 | 0.76 | CARM1 (0.44) | SMN1; SMN2 | |
| SCHEMBL16271565 | 0.76 | ALDH1A1 (0.41) | KDM4EALDH1A1KMT2ALMNAHPGD | |
| SCHEMBL1708734 | 0.75 | — | — | |
| SCHEMBL7289691 | 0.75 | — | — | |
| SCHEMBL3035191 | 0.74 | HSD17B10 (0.52) | KDM4EALDH1A1LMNASMN1; SMN2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651237-A4 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2008-10-01 | — | — | EP | claimed |
| EP-1651237-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | Galileo Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005016270-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | GALILEO PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | JOHNSON & JOHNSON CONSUMER INC. | 2005-02-10 | — | — | US | claimed |
| EP-4230264-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2026-01-28 | — | — | EP | disclosed |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-04-24 | — | — | US | disclosed |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2024-09-03 | — | — | US | disclosed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-4230264-A2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2023-08-23 | — | — | EP | disclosed |
| EP-3366668-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2023-06-21 | — | — | EP | disclosed |
| EP-0087659-A2 | Process for the preparation of cyclic N-vinyl acyl amines | BAYER AG (DE) | 1983-09-07 | — | — | EP | disclosed |
| EP-0084966-A2 | Aqueous compositions containing overbased materials | The Lubrizol Corporation (US) | 1983-08-03 | — | — | EP | disclosed |
| US-4368133-A | Aqueous systems containing nitrogen-containing, phosphorous-free carboxylic solubilizer/surfactant additives | THE LUBRIZOL CORPORATION (US) | 1983-01-11 | — | — | US | disclosed |
| US-4234435-A | Novel carboxylic acid acylating agents, derivatives thereof, concentrate and lubricant compositions containing the same, and processes for their preparation | THE LUBRIZOL CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
| US-4105571-A | ZINC DIHYDROCARBYL DITHIOPHOSPHATE, ESTER OF A POLYCARBOXYLIC ACID AND A GLYCOL, ASHLESS DISPERSANT | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4009195-A | FROM 1-ALKENES AND ACRYLIC ACID DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
| US-3994958-A | OF 1-ALKENES AND ACRYLIC ACID DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3968148-A | Copolymers of 1-alkenes and acrylic acid derivatives | ROHM AND HAAS COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | KDM4E 1909/4885ALDH1A1 363/4885KMT2A 2595/4885 |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | KDM4E 1909/4885ALDH1A1 363/4885KMT2A 2595/4885 |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | KDM4E 1909/4885ALDH1A1 363/4885KMT2A 2595/4885 |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | KRT18, CUTA, TUBB1 | KDM4E 1588/4885ALDH1A1 458/4885KMT2A 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.